SEC 13F Intelligence

Managers / Q2 2019 · view latest →

Essex Woodlands Management, Inc.

CIK 0001542339 · 21 WATERWAY AVE, STE 150, THE WOODLANDS, TX, 77380 · 281-364-1555

Reported Value
$173M
Q2 2019
Positions
6
Filings on Record
30
2019–present window
Filed
Aug 14, 2019
original filing

Summary

Essex Woodlands Management, Inc. reported $173M in U.S.-listed holdings across 6 positions for Q2 2019.

The portfolio is heavily concentrated: PSDVUSD alone accounts for 39.6% of reported value.

Compared with Q1 2019, the fund opened 3 new positions and exited 5.

Portfolio Metrics

Turnover
+38.6%
vs prior filed quarter
Largest Position
+39.6%
Eyepoint Pharmaceuticals
New / Exited
3 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $251MQ4 ’18Q1 ’19: $201MQ2 ’19: $173MQ3 ’19: $161MQ4 ’19: $214MQ4 ’19Q1 ’20: $155MQ2 ’20: $204MQ3 ’20: $188MQ4 ’20: $385MQ4 ’20Q1 ’21: $640MQ2 ’21: $677MQ3 ’21: $451MQ4 ’21: $445MQ4 ’21Q1 ’22: $414MQ2 ’22: $242MQ3 ’22: $242MQ4 ’22: $179MQ4 ’22Q1 ’23: $173MQ2 ’23: $132MQ3 ’23: $113MQ4 ’23: $404MQ4 ’23Q1 ’24: $345MQ2 ’24: $307MQ3 ’24: $350MQ4 ’24: $433MQ4 ’24Q1 ’25: $347MQ2 ’25: $279MQ3 ’25: $307MQ4 ’25: $318MQ4 ’25Q1 ’26: $251Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 99.7%Other: 0.3%
  • Common Stock · 99.7% · $173M
  • Other · 0.3% · $579,000

Quarter-over-Quarter Changes full breakdown →

vs Q1 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
PSDVUSDEYEPOINT PHARMACEUTICALS INCNEW+41.91M41.91M+$69M$69M
ELGXEURENDOLOGIX INCNEW+125.7K125.7K+$1M$1M
CATALYST BIOSCIENCES INCNEW+78.6K78.6K+$579,000$579,000
EYEPOINTSOLD OUT−41.91M0−$75M$0
CORIUMSOLD OUT+00−$3M$0
ENDOLOGIX INCSOLD OUT−1.26M0−$1M$0
CATALYSTSOLD OUT−78.6K0−$640,000$0
ACURACURA PHARMACEUTICALS INCSOLD OUT−1.96M0−$352,000$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2019

6 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1PSDVUSDEYEPOINT PHARMACEUTICALS INChistory →COM39.63%$69M41.91M
2AXGNAXOGEN INChistory →COM27.74%$48M2.43M
3RVNCEURREVANCE THERAPEUTICS INChistory →COM24.99%$43M3.34M
44875MEDICINOVA INChistory →COM NEW6.50%$11M1.17M
5ELGXEURENDOLOGIX INCCOM NEW0.80%$1M125.7K
6CATALYST BIOSCIENCES INCCOM NEW0.33%$579,00078.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$251M5May 4, 202613F-HRchanges · EDGAR ↗
Q4 2025$318M6Feb 4, 202613F-HRchanges · EDGAR ↗
Q3 2025$307M6Nov 12, 202513F-HRchanges · EDGAR ↗
Q2 2025$279M6Aug 7, 202513F-HRchanges · EDGAR ↗
Q1 2025$347M6May 13, 202513F-HRchanges · EDGAR ↗
Q4 2024$433M7Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$350M7Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$307M7Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$345M7May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$404M7Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$113M6Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$132M6Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$173M7May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$179M7Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$242M7Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$242M9Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$414M9May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$445M10Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$451M9Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$677M9Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$640M9May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$385M8Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$188M8Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$204M8Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$155M8May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$214M8Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$161M6Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$173M6Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$201M8May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$251M8Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.